NEWS & EVENTS

Inotrem’s COVID-19 Phase IIa Clinical Trial declared “National Priority Research” by the French government’s Clinical Trial Council

Paris, December 24. 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government’ steering committee for therapeutic clinical trials and other research (CAPNET).

Read full article (PDF) 

 

luctus Donec amet, consectetur elit. libero efficitur. eleifend Aliquam